(AXSM) Axsome Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 8.210m USD | Total Return: 53.8% in 12m

Stock Mental Health, Sleep Disorders, Migraine
Total Rating 43
Risk 28
Buy Signal 0.42
Biotechnology +0.2
Pharmaceuticals -0.1
Market Cap: 8,210m
Avg Trading Vol: 78.8M USD
ATR: 3.44%
Peers RS (IBD): 61.4
Risk 5d forecast
Volatility44.6%
Rel. Tail Risk-11.2%
Reward TTM
Sharpe Ratio1.00
Alpha35.40
Character TTM
Beta0.209
Beta Downside1.303
Drawdowns 3y
Max DD36.45%
CAGR/Max DD1.15
EPS (Earnings per Share) EPS (Earnings per Share) of AXSM over the last years for every Quarter: "2021-03": -0.78, "2021-06": -0.86, "2021-09": -0.93, "2021-12": -0.9, "2022-03": -1.03, "2022-06": -1.06, "2022-09": -1.07, "2022-12": -1.41, "2023-03": -0.26, "2023-06": -1.54, "2023-09": -1.32, "2023-12": -2.08, "2024-03": -1.44, "2024-06": -1.67, "2024-09": -1.3419, "2024-12": -1.54, "2025-03": -1.2157, "2025-06": -0.97, "2025-09": -0.95, "2025-12": -0.56, "2026-03": 0,
EPS CAGR: 19.07%
EPS Trend: 33.6%
Last SUE: 2.68
Qual. Beats: 1
Revenue Revenue of AXSM over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 8.82, 2022-09: 16.846, 2022-12: 24.371528, 2023-03: 94.576, 2023-06: 46.7, 2023-09: 57.794, 2023-12: 71.53, 2024-03: 74.999, 2024-06: 87.166, 2024-09: 104.762, 2024-12: 118.766, 2025-03: 121.463, 2025-06: 150.042, 2025-09: 170.992, 2025-12: 195.999, 2026-03: null,
Rev. CAGR: 136.36%
Rev. Trend: 81.1%
Last SUE: 0.63
Qual. Beats: 0
Description: AXSM Axsome Therapeutics March 05, 2026

Axsome Therapeutics, Inc. (AXSM) is a biopharmaceutical company focused on central nervous system (CNS) disorders. The company develops and commercializes novel therapies for conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine. The pharmaceutical sector is characterized by high research and development costs and a lengthy drug approval process.

AXSMs commercial products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness, and Symbravo for migraine. The companys pipeline includes candidates for Alzheimers disease agitation, smoking cessation, narcolepsy, fibromyalgia, and other conditions. Biopharmaceutical companies often rely on a portfolio approach, balancing marketed products with a pipeline of investigational therapies.

To further explore AXSMs financial performance and market position, consider reviewing its detailed financials on ValueRay.

Headlines to Watch Out For
  • Auvelity sales drive revenue growth for depression treatment
  • Sunosi sales contribute to narcolepsy and sleep apnea revenue
  • Pipeline drug AXS-05 regulatory approval for Alzheimers agitation
  • AXS-12 and AXS-14 clinical trial success impacts future revenue
  • Competition from other CNS disorder treatments affects market share
Piotroski VR‑10 (Strict, 0-10) 3.0
Net Income: -183.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.14 > 0.02 and ΔFCF/TA 8.99 > 1.0
NWC/Revenue: 32.91% < 20% (prev 66.10%; Δ -33.19% < -1%)
CFO/TA -0.14 > 3% & CFO -93.4m > Net Income -183.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.55 > 1.5 & < 3
Outstanding Shares: last quarter (50.6m) vs 12m ago 4.30% < -2%
Gross Margin: 92.56% > 18% (prev 0.91%; Δ 9.17k% > 0.5%)
Asset Turnover: 101.5% > 50% (prev 67.84%; Δ 33.64% > 0%)
Interest Coverage Ratio: -26.67 > 6 (EBITDA TTM -166.5m / Interest Expense TTM 6.56m)
Altman Z'' -8.32
A: 0.30 (Total Current Assets 589.0m - Total Current Liabilities 378.8m) / Total Assets 689.8m
B: -1.89 (Retained Earnings -1.31b / Total Assets 689.8m)
C: -0.28 (EBIT TTM -174.9m / Avg Total Assets 629.2m)
D: -2.17 (Book Value of Equity -1.31b / Total Liabilities 601.5m)
Altman-Z'' Score: -8.32 = D
Beneish M -2.83
DSRI: 0.95 (Receivables 224.5m/142.0m, Revenue 638.5m/385.7m)
GMI: 0.99 (GM 92.56% / 91.37%)
AQI: 0.85 (AQ_t 0.12 / AQ_t-1 0.14)
SGI: 1.66 (Revenue 638.5m / 385.7m)
TATA: -0.13 (NI -183.2m - CFO -93.4m) / TA 689.8m)
Beneish M-Score: -2.83 (Cap -4..+1) = A
What is the price of AXSM shares? As of April 02, 2026, the stock is trading at USD 169.02 with a total of 669,188 shares traded.
Over the past week, the price has changed by +6.18%, over one month by +3.25%, over three months by -3.87% and over the past year by +53.83%.
Is AXSM a buy, sell or hold? Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
  • StrongBuy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AXSM price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 223.7 32.3%
Analysts Target Price 223.7 32.3%
AXSM Fundamental Data Overview April 01, 2026
P/E Forward = 333.3333
P/S = 12.8585
P/B = 92.927
Revenue TTM = 638.5m USD
EBIT TTM = -174.9m USD
EBITDA TTM = -166.5m USD
Long Term Debt = 117.7m USD (from longTermDebt, last quarter)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 241.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -81.6m USD (from netDebt column, last quarter)
Enterprise Value = 8.13b USD (8.21b + Debt 241.3m - CCE 322.9m)
Interest Coverage Ratio = -26.67 (Ebit TTM -174.9m / Interest Expense TTM 6.56m)
EV/FCF = -86.64x (Enterprise Value 8.13b / FCF TTM -93.8m)
FCF Yield = -1.15% (FCF TTM -93.8m / Enterprise Value 8.13b)
FCF Margin = -14.69% (FCF TTM -93.8m / Revenue TTM 638.5m)
Net Margin = -28.69% (Net Income TTM -183.2m / Revenue TTM 638.5m)
Gross Margin = 92.56% ((Revenue TTM 638.5m - Cost of Revenue TTM 47.5m) / Revenue TTM)
Gross Margin QoQ = 93.71% (prev 93.03%)
Tobins Q-Ratio = 11.78 (Enterprise Value 8.13b / Total Assets 689.8m)
Interest Expense / Debt = 0.49% (Interest Expense 1.17m / Debt 241.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -138.1m (EBIT -174.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 589.0m / Total Current Liabilities 378.8m)
Debt / Equity = 2.73 (Debt 241.3m / totalStockholderEquity, last quarter 88.3m)
 Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -81.6m / EBITDA -166.5m)
 Debt / FCF = 0.87 (negative FCF - burning cash) (Net Debt -81.6m / FCF TTM -93.8m)
 Total Stockholder Equity = 72.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.11% (Net Income -183.2m / Total Assets 689.8m)
RoE = -254.1% (Net Income TTM -183.2m / Total Stockholder Equity 72.1m)
RoCE = -92.12% (EBIT -174.9m / Capital Employed (Equity 72.1m + L.T.Debt 117.7m))
 RoIC = -53.51% (negative operating profit) (NOPAT -138.1m / Invested Capital 258.2m)
 WACC = 6.54% (E(8.21b)/V(8.45b) * Re(6.72%) + D(241.3m)/V(8.45b) * Rd(0.49%) * (1-Tc(0.21)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 3.43%
 [DCF] Fair Price = unknown (Cash Flow -93.8m)
 EPS Correlation: 33.61 | EPS CAGR: 19.07% | SUE: 2.68 | # QB: 1
Revenue Correlation: 81.15 | Revenue CAGR: 136.4% | SUE: 0.63 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.55 | Chg7d=+0.000 | Chg30d=-0.253 | Revisions Net=-4 | Analysts=7
EPS current Year (2026-12-31): EPS=-1.04 | Chg7d=+0.000 | Chg30d=-1.387 | Revisions Net=-6 | Growth EPS=+70.0% | Growth Revenue=+54.7%
EPS next Year (2027-12-31): EPS=5.76 | Chg7d=+0.001 | Chg30d=-0.863 | Revisions Net=-6 | Growth EPS=+653.0% | Growth Revenue=+56.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
Additional Sources for AXSM Stock Fund Manager Positions: Dataroma · Stockcircle